The molecular genetic basis for hypertrophic cardiomyopathy.

Hypertrophic cardiomyopathy (HCM), a relatively common disease, is diagnosed clinically by unexplained cardiac hypertrophy and pathologically by myocyte hypertrophy, disarray, and interstitial fibrosis. HCM is the most common cause of sudden cardiac death (SCD) in the young and a major cause of morbidity and mortality in elderly. Hypertrophy and fibrosis are the major determinants of morbidity and SCD. More than 100 mutations in nine genes, all encoding sarcomeric proteins have been identified in patients with HCM, which had led to the notion that HCM is a disease of contractile sarcomeric proteins. The beta -myosin heavy chain (MyHC), cardiac troponin T (cTnT) and myosin binding protein-C (MyBP-C) are the most common genes accounting for approximately 2/3 of all HCM cases. Genotype-phenotype correlation studies suggest that mutations in the beta -MyHC gene are associated with more extensive hypertrophy and a higher risk of SCD as compared to mutations in genes coding for other sarcomeric proteins, such as MyBP-C and cTnT. The prognostic significance of mutations is related to their hypertrophic expressivity and penetrance, with the exception of those in the cTnT, which are associated with mild hypertrophic response and a high incidence of SCD. However, there is a significant variability and factors, such as modifier genes and probably the environmental factors affect the phenotypic expression of HCM. The molecular pathogenesis of HCM is not completely understood. In vitro and in vivo studies suggest that mutations impart a diverse array of functional defects including reduced ATPase activity of myosin, acto-myosin interaction, cross-bridging kinetics, myocyte contractility, and altered Ca2+ sensitivity. Hypertrophy and other clinical and pathological phenotypes are considered compensatory phenotypes secondary to functional defects. In summary, the molecular genetic basis of HCM has been identified, which affords the opportunity to delineate its pathogenesis. Understanding the pathogenesis of HCM could provide for genetic based diagnosis, risk stratification, treatment and prevention of cardiac phenotypes.

[1]  S Sasayama,et al.  Ventricular Expression of Brain Natriuretic Peptide in Hypertrophic Cardiomyopathy , 1993, Circulation.

[2]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[3]  G. Cuda,et al.  A previously undescribed de novo insertion-deletion mutation in the beta myosin heavy chain gene in a kindred with familial hypertrophic cardiomyopathy. , 1996, Heart.

[4]  M. Gautel,et al.  Phosphorylation switches specific for the cardiac isoform of myosin binding protein‐C: a modulator of cardiac contraction? , 1995, The EMBO journal.

[5]  A. Marian,et al.  Detection of a new mutation in the beta-myosin heavy chain gene in an individual with hypertrophic cardiomyopathy. , 1992, The Journal of clinical investigation.

[6]  H. Katus,et al.  Transgenic rat hearts expressing a human cardiac troponin T deletion reveal diastolic dysfunction and ventricular arrhythmias. , 2000, Cardiovascular research.

[7]  T. Hewett,et al.  A truncated cardiac troponin T molecule in transgenic mice suggests multiple cellular mechanisms for familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[8]  T. Hewett,et al.  A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[9]  D. Szczesna,et al.  Abnormal Contractile Function in Transgenic Mice Expressing a Familial Hypertrophic Cardiomyopathy-linked Troponin T (I79N) Mutation* , 2001, The Journal of Biological Chemistry.

[10]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[11]  T. Hewett,et al.  In vivo modeling of myosin binding protein C familial hypertrophic cardiomyopathy. , 1999, Circulation research.

[12]  P. Lange,et al.  Regulation of human heart contractility by essential myosin light chain isoforms. , 1996, The Journal of clinical investigation.

[13]  L. Fananapazir,et al.  Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. , 1995, The Journal of clinical investigation.

[14]  L. Leinwand,et al.  Mice Expressing Mutant Myosin Heavy Chains Are a Model for Familial Hypertrophic Cardiomyopathy , 1996, Molecular medicine.

[15]  C. E. Seidman,et al.  Molecular genetic studies of familial hypertrophic cardiomyopathy , 1998, Basic Research in Cardiology.

[16]  S. Solomon,et al.  Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1. , 1989, The New England journal of medicine.

[17]  A. Marian,et al.  Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death , 1993, The Lancet.

[18]  J. Metzger,et al.  Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. , 1999, The Journal of clinical investigation.

[19]  F. Chiarella,et al.  Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy. , 1992, The American journal of cardiology.

[20]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[21]  J. Beckmann,et al.  Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[22]  M. Ikebe,et al.  Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. , 1996, The Journal of clinical investigation.

[23]  J. Metzger,et al.  Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant α-tropomyosins in adult cardiac myocytes , 1999, Nature Medicine.

[24]  K. Bailey,et al.  Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. , 1995, Circulation.

[25]  A. Marian,et al.  Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[26]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[27]  A. Marian,et al.  Sudden cardiac death in hypertrophic cardiomyopathy , 1995 .

[28]  M. Gautel,et al.  A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. , 1996, European journal of biochemistry.

[29]  M. Matsuzaki,et al.  Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy , 1997, Nature Genetics.

[30]  R. Brugada,et al.  Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. , 1997, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[31]  K. Chien,et al.  Point Mutations in Human β Cardiac Myosin Heavy Chain Have Differential Effects on Sarcomeric Structure and Assembly: An ATP Binding Site Change Disrupts Both Thick and Thin Filaments, Whereas Hypertrophic Cardiomyopathy Mutations Display Normal Assembly , 1997, The Journal of cell biology.

[32]  J. Seidman,et al.  Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. , 2000, Circulation research.

[33]  J. Seidman,et al.  Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice. , 1997, The Journal of clinical investigation.

[34]  H. Watkins,et al.  Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Matsumori,et al.  Endothelin-1 and its receptor in hypertrophic cardiomyopathy. , 1996, Hypertension.

[36]  T. Kishimoto,et al.  A novel deletion mutation in the beta-myosin heavy chain gene found in Japanese patients with hypertrophic cardiomyopathy. , 1995, Journal of molecular and cellular cardiology.

[37]  W. Roberts,et al.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.

[38]  A. Marian.  Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy , 2000, The Lancet.

[39]  M. Komajda,et al.  Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. , 1997, Circulation research.

[40]  F. Reinach,et al.  The troponin complex and regulation of muscle contraction , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  G. Cuda,et al.  Isometric tension and mutant myosin heavy chain content in single skeletal myofibers from hypertrophic cardiomyopathy patients. , 1997, Journal of molecular and cellular cardiology.

[42]  A. Børglum,et al.  α-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy , 1999 .

[43]  B. Swynghedauw.  Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. , 1986, Physiological reviews.

[44]  J. Seidman,et al.  Targeted Ablation of the Murine α-Tropomyosin Gene , 1997 .

[45]  D. Warshaw,et al.  In Vivo Analysis of an Essential Myosin Light Chain Mutation Linked to Familial Hypertrophic Cardiomyopathy , 2000, Circulation research.

[46]  J. Schleich,et al.  The complete sequence of the human beta-myosin heavy chain gene and a comparative analysis of its product. , 1990, Genomics.

[47]  J. Seidman,et al.  Homozygous Mutation in Cardiac Troponin T: Implications for Hypertrophic Cardiomyopathy , 2000, Circulation.

[48]  Frederick J. Schoen,et al.  A Mouse Model of Familial Hypertrophic Cardiomyopathy , 1996, Science.

[49]  Guiping Yang,et al.  An α-cardiac myosin heavy chain gene mutation impairs contraction and relaxation function of cardiac myocytes. , 1999, American journal of physiology. Heart and circulatory physiology.

[50]  I. Ohtsuki,et al.  Ca2+ Sensitization and Potentiation of the Maximum Level of Myofibrillar ATPase Activity Caused by Mutations of Troponin T Found in Familial Hypertrophic Cardiomyopathy* , 1999, The Journal of Biological Chemistry.

[51]  C. Hengstenberg,et al.  Familial hypertrophic cardiomyopathy. Microsatellite haplotyping and identification of a hot spot for mutations in the beta-myosin heavy chain gene. , 1993, The Journal of clinical investigation.

[52]  S. Solomon,et al.  Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. , 1994, The Journal of clinical investigation.

[53]  V. Ferrans,et al.  The stretch-activation response may be critical to the proper functioning of the mammalian heart. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Entman,et al.  Decreased left ventricular ejection fraction in transgenic mice expressing mutant cardiac troponin T-Q(92), responsible for human hypertrophic cardiomyopathy. , 2000, Journal of molecular and cellular cardiology.

[55]  R. Solaro,et al.  Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments. , 1998, Circulation research.

[56]  W. Williams,et al.  Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. , 1997, Circulation.

[57]  M Hiroe,et al.  Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. , 1999, Biochemical and biophysical research communications.

[58]  M. Komajda,et al.  Genotype-phenotype correlations in familial hypertrophic cardiomyopathy. A comparison between mutations in the cardiac protein-C and the beta-myosin heavy chain genes. , 1998, European heart journal.

[59]  E. Homsher,et al.  Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy. , 1996, The Journal of clinical investigation.

[60]  M. Quiñones,et al.  Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. , 2000, Journal of molecular and cellular cardiology.

[61]  I. Rayment,et al.  Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle , 1996, Nature Genetics.

[62]  A J Marian,et al.  A transgenic rabbit model for human hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[63]  T. Hewett,et al.  Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart. , 1996, The Journal of clinical investigation.

[64]  M. Quiñones,et al.  Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. , 1995, Circulation.

[65]  J. Seidman,et al.  Altered cardiac excitation-contraction coupling in mutant mice with familial hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[66]  B. Kay,et al.  Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. , 1995, Circulation research.

[67]  W. Rottbauer,et al.  Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. , 1997, The Journal of clinical investigation.

[68]  W. Roberts,et al.  Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum of Patients with Hypertrophic Cardiomyopathy , 1979, Circulation.

[69]  H. Sugi,et al.  Characterization of mutant myosins of Dictyostelium discoideum equivalent to human familial hypertrophic cardiomyopathy mutants. Molecular force level of mutant myosins may have a prognostic implication. , 1997, The Journal of clinical investigation.

[70]  G. Boivin,et al.  Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction. , 1999, Circulation research.

[71]  K. Trybus,et al.  Skeletal muscle myosin light chains are essential for physiological speeds of shortening , 1993, Nature.

[72]  P Corvol,et al.  An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.

[73]  J. Seidman,et al.  Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. , 1999, Circulation research.

[74]  D. Mann,et al.  Expression of a Mutation Causing Hypertrophic Cardiomyopathy Disrupts Sarcomere Assembly in Adult Feline Cardiac Myocytes , 1995 .

[75]  A. Simcox,et al.  Impairment of muscle function caused by mutations of phosphorylation sites in myosin regulatory light chain , 1995, Nature.

[76]  L. Fananapazir,et al.  Differences in Clinical Expression of Hypertrophic Cardiomyopathy Associated With Two Distinct Mutations in the β‐Myosin Heavy Chain Gene: A 908Leu→Val Mutation and a 403Arg→gGln Mutation , 1992, Circulation.

[77]  M. Komajda,et al.  Genotype‐phenotype analysis in four families with mutations in β‐myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy , 1998, Human mutation.

[78]  D. Kass,et al.  Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. , 1999, The Journal of clinical investigation.

[79]  M. Komajda,et al.  The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. , 1997, Journal of molecular and cellular cardiology.

[80]  H. Watkins,et al.  Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility. , 1997, Biochemical and biophysical research communications.

[81]  J. Stull,et al.  Myosin light chain phosphorylation in vertebrate striated muscle: regulation and function. , 1993, The American journal of physiology.

[82]  M. Entman,et al.  Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. , 1998, The Journal of clinical investigation.

[83]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[84]  T. Meitinger,et al.  A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated β-myosin heavy chain genes , 1998, Human Genetics.

[85]  M. Komajda,et al.  Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. , 1998, Circulation.

[86]  J. Seidman,et al.  Independent origin of identical beta cardiac myosin heavy-chain mutations in hypertrophic cardiomyopathy. , 1993, American journal of human genetics.

[87]  L. Leinwand,et al.  Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. , 1994, The Journal of biological chemistry.

[88]  A. Marian,et al.  Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. , 1997, Circulation research.

[89]  M. Yacoub,et al.  Codon 102 of the cardiac troponin T gene is a putative hot spot for mutations in familial hypertrophic cardiomyopathy. , 1996, Circulation.

[90]  T. Hewett,et al.  Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy. , 2000, Circulation research.

[91]  Cardiomyopathies and mitochondrial DNA mutations , 1997 .

[92]  T. Hewett,et al.  Molecular and Physiological Effects of α-Tropomyosin Ablation in the Mouse , 1998 .

[93]  J. Seidman,et al.  Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. , 1998, The Journal of clinical investigation.

[94]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[95]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[96]  J. Seidman,et al.  Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action. , 1996, The Journal of clinical investigation.

[97]  I. Ohtsuki,et al.  Ca2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. , 1998, American journal of physiology. Cell physiology.

[98]  L. Leinwand,et al.  Cardiac myosin heavy chains lacking the light chain binding domain cause hypertrophic cardiomyopathy in mice. , 1999, American journal of physiology. Heart and circulatory physiology.

[99]  Dimitrios Georgakopoulos,et al.  The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an α-cardiac myosin heavy chain missense mutation , 1999, Nature Medicine.

[100]  Christine E. Seidman,et al.  α-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere , 1994, Cell.

[101]  T. Hewett,et al.  Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. , 1999, The Journal of clinical investigation.

[102]  F O Mueller,et al.  Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. , 1996, JAMA.

[103]  M. Quiñones,et al.  Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. , 1999, Circulation.

[104]  S. Winegrad.  Cardiac myosin binding protein C. , 1999, Circulation research.

[105]  J. Spudich,et al.  Single myosin molecule mechanics: piconewton forces and nanometre steps , 1994, Nature.

[106]  T. Hewett,et al.  Transgenic remodeling of the regulatory myosin light chains in the mammalian heart. , 1997, Circulation research.